SEC Info - Pure Bioscience, Inc. - ‘8-K’ for 10/28/22

SEC Info℠

Home

Help

Please Sign In

Pure Bioscience, Inc. – ‘8-K’ for 10/28/22

On: Friday, 10/28/22, at 4:05pm ET · For: 10/28/22 · Accession #: 1493152-22-29839 · File #: 1-14468

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/28/22  Pure Bioscience, Inc.             8-K:2,9    10/28/22   11:301K                                   M2 Compliance LLC/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     36K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     82K 
 6: R1          Cover                                               HTML     42K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- form8-k_htm                         XML     14K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- pure-20221028_lab                     XML     98K 
 5: EX-101.PRE  XBRL Presentations -- pure-20221028_pre              XML     65K 
 3: EX-101.SCH  XBRL Schema -- pure-20221028                         XSD     13K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
11: ZIP         XBRL Zipped Folder -- 0001493152-22-029839-xbrl      Zip     25K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0001006028 i false 0001006028 2022-10-28 2022-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i October 28, 2022

i PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

i Delaware		i 001-14468		i 33-0530289
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i 9669 Hermosa Avenue i Rancho Cucamonga, i California		i 91730
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: i (619) i 596-8600

i Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On October 28, 2022, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year ended July 31, 2022 and related information. A copy of the press release is attached as Exhibit 99.1.

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

	99.1	Press Release, dated October 28 2022.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PURE BIOSCIENCE, INC.

Dated: October 28, 2022	By:	/s/ Tom Y. Lee
		Tom Y. Lee
		Chief Executive Officer

EXHIBIT INDEX

*Exhibit* *Number*		*Description*

99.1		Press Release, dated October 28, 2022.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	10/28/22	None on these Dates
	7/31/22
		List all Filings

↑Top

Filing Submission 0001493152-22-029839 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)